BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777 [PMID: 22371636 DOI: 10.3748/wjg.v18.i8.767]
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/767.htm
Number Citing Articles
1
R. Ennaifer, N. Elleuch, M. Cheikh, H. Romdhane, H. Ben Nejma, N. Bel Hadj. La rifaximine : une nouvelle alternative dans la prévention des infections bactériennes chez le cirrhotique ?Journal Africain d'Hépato-Gastroentérologie 2015; 9(3): 122 doi: 10.1007/s12157-015-0606-8
2
Rebeca Nevado, Raquel Forcén, Elena Layunta, María Divina Murillo, Laura Grasa. Neomycin and bacitracin reduce the intestinal permeability in mice and increase the expression of some tight-junction proteinsRevista Española de Enfermedades Digestivas 2015; 107 doi: 10.17235/reed.2015.3868/2015
3
Hiroshi Fukui, Hidetsugu Saito, Yoshiyuki Ueno, Hirofumi Uto, Katsutoshi Obara, Isao Sakaida, Akitaka Shibuya, Masataka Seike, Sumiko Nagoshi, Makoto Segawa, Hirohito Tsubouchi, Hisataka Moriwaki, Akinobu Kato, Etsuko Hashimoto, Kojiro Michitaka, Toshikazu Murawaki, Kentaro Sugano, Mamoru Watanabe, Tooru Shimosegawa. Evidence-based clinical practice guidelines for liver cirrhosis 2015Journal of Gastroenterology 2016; 51(7): 629 doi: 10.1007/s00535-016-1216-y
4
Xianghui Han, Zhanyang Luo, Wenyi Wang, Peiyong Zheng, Tian Li, Zubing Mei, Jianyi Wang. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic EncephalopathyFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.696065
5
Ming Bai, Zhiping Yang, Xingshun Qi, Daiming Fan, Guohong Han. l -ornithine-l -aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trialsJournal of Gastroenterology and Hepatology 2013; 28(5): 783 doi: 10.1111/jgh.12142
6
Nina Kimer, Aleksander Krag, Flemming Bendtsen, Søren Møller, Lise Lotte Gluud. Rifaximin for people with hepatic encephalopathyCochrane Database of Systematic Reviews 2015;  doi: 10.1002/14651858.CD011585
7
Kosuke Kaji, Norihisa Nishimura, Kei Moriya, Hitoshi Yoshiji. Clinical Investigation of Portal Hypertension2019; : 533 doi: 10.1007/978-981-10-7425-7_55
8
Philipp Lutz, Hans Dieter Nischalke, Christian P Strassburg, Ulrich Spengler. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liverWorld Journal of Hepatology 2015; 7(3): 304-314 doi: 10.4254/wjh.v7.i3.304
9
Mohammadreza Naderian, Heshmatollah Akbari, Morteza Saeedi, Amir Ali Sohrabpour. olyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled TrialMiddle East Journal of Digestive Diseases 2017; 9(1): 12 doi: 10.15171/mejdd.2016.46
10
Olivier Braissant, Valérie A. McLin, Cristina Cudalbu. Ammonia toxicity to the brainJournal of Inherited Metabolic Disease 2013; 36(4): 595 doi: 10.1007/s10545-012-9546-2
11
Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, Chuan-Yong Guo. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-AnalysisGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/236963
12
José M. Ferro, Pedro Viana, Patrícia Santos. Management of Neurologic Manifestations in Patients with Liver DiseaseCurrent Treatment Options in Neurology 2016; 18(8) doi: 10.1007/s11940-016-0419-0
13
Stephen M. Riordan. Liver Diseases2020; : 695 doi: 10.1007/978-3-030-24432-3_64
14
RIFAXIMINGastroenterology Nursing 2013; 36(2): 140 doi: 10.1097/SGA.0b013e31828a02a0
15
Mitsuhiko Shibasaki, Takeshi Hatanaka, Yasushi Shimada, Tamon Nagashima, Masashi Namikawa, Shuichi Saito, Kenichi Hosonuma, Atsushi Naganuma, Daichi Takizawa, Hirotaka Arai, Takashi Kosone, Hitoshi Takagi, Ken Sato, Satoru Kakizaki, Toshio Uraoka. Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathyKanzo 2020; 61(1): 1 doi: 10.2957/kanzo.61.1
16
Fiona Chautant, Maeva Guillaume, Marie-Angèle Robic, Jean-François Cadranel, Jean-Marie Peron, Hortensia Lison, Charlène Cool, Christophe Bureau, Véronique Duhalde. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathyWorld Journal of Hepatology 2020; 12(1): 10-20 doi: 10.4254/wjh.v12.i1.10
17
Sudhir Maharshi, Barjesh Chander Sharma, Siddharth Srivastava, Amit Jindal. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleedGut 2015; 64(8): 1341 doi: 10.1136/gutjnl-2014-308521
18
Reena Rajasuriar, Gabriela Khoury, Adeeba Kamarulzaman, Martyn A. French, Paul U. Cameron, Sharon R. Lewin. Persistent immune activation in chronic HIV infectionAIDS 2013; 27(8): 1199 doi: 10.1097/QAD.0b013e32835ecb8b
19
David Holt. Small Animal Critical Care Medicine2015; : 458 doi: 10.1016/B978-1-4557-0306-7.00088-X
20
Motoh Iwasa, Yoshiyuki Takei. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremiaHepatology Research 2015; 45(12): 1155 doi: 10.1111/hepr.12495
21
Eamonn M.M. Quigley, Catherine Stanton, Eileen F. Murphy. The gut microbiota and the liver. Pathophysiological and clinical implicationsJournal of Hepatology 2013; 58(5): 1020 doi: 10.1016/j.jhep.2012.11.023
22
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathyRevista de Gastroenterología de México (English Edition) 2020; 85(1): 56 doi: 10.1016/j.rgmxen.2019.09.003
23
Christopher F. Rose, Piero Amodio, Jasmohan S. Bajaj, Radha Krishan Dhiman, Sara Montagnese, Simon D. Taylor-Robinson, Hendrik Vilstrup, Rajiv Jalan. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapyJournal of Hepatology 2020; 73(6): 1526 doi: 10.1016/j.jhep.2020.07.013
24
E. Roeb, M. Roderfeld. Mikrobiom zwischen Intestinum und LeberDer Gastroenterologe 2015; 10(2): 111 doi: 10.1007/s11377-014-0961-9
25
Stephen M. Riordan, Roger Williams. Neurocritical Care2019; : 370 doi: 10.1017/9781107587908.030
26
Praveen Sharma, Barjesh C. Sharma. Management of Overt Hepatic EncephalopathyJournal of Clinical and Experimental Hepatology 2015; 5: S82 doi: 10.1016/j.jceh.2014.04.004
27
P. Lutz, M. Parcina, I. Bekeredjian-Ding, A. Hoerauf, C. P. Strassburg, U. Spengler. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximinInfection 2014; 42(1): 175 doi: 10.1007/s15010-013-0449-4
28
Liz Toapanta-Yanchapaxi, Jorge A. López-Velázquez, Misael Uribe, Nahum Méndez-Sánchez. Minimal hepatic encephalopathy. Should we treat it?Annals of Hepatology 2013; 12(3): 487 doi: 10.1016/S1665-2681(19)31013-0
29
Juan Cordoba. Hepatic Encephalopathy: From the Pathogenesis to the New TreatmentsISRN Hepatology 2014; 2014: 1 doi: 10.1155/2014/236268
30
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035
31
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepáticaRevista de Gastroenterología de México 2020; 85(1): 56 doi: 10.1016/j.rgmx.2019.09.001
32
Use of Oral Antibiotics in Elderly Gastrointestinal PatientsJournal of the Korean Geriatrics Society 2012; 16(3): 108 doi: 10.4235/jkgs.2012.16.3.108
33
Praveen Sharma, Barjesh Chander Sharma. Disaccharides in the treatment of hepatic encephalopathyMetabolic Brain Disease 2013; 28(2): 313 doi: 10.1007/s11011-013-9392-4
34
Donna M. Zucker, Rhoda Redulla. Lactulose Management of Minimal Hepatic EncephalopathyGastroenterology Nursing 2019; 42(1): 84 doi: 10.1097/SGA.0000000000000429
35
Khaled Amer, Mohamed S. Hashim, Eman Abd El Sameea, Manar Obada, Mostafa G. El Helbawy, Ahmed Edrees, Tary A. Salman, Omkolsoum Al Haddad, Mohsen Salama. Evaluation of rifaximin in Egyptian patients with hepatic encephalopathyEgyptian Liver Journal 2013; 3(4): 113 doi: 10.1097/01.ELX.0000433599.23047.b1
36
Roberto Lorenzetti, Cosimo Prantera. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial resultsClinical Investigation 2013; 3(12): 1187 doi: 10.4155/cli.13.96
37
Sahaj Rathi, Radha K. Dhiman. Hepatobiliary Quiz (Answers)—14 (2015)Journal of Clinical and Experimental Hepatology 2015; 5(2): 175 doi: 10.1016/j.jceh.2015.06.007
38
Kristina R. Chacko, Samuel H. Sigal. Update on Management of Patients With Overt Hepatic EncephalopathyHospital Practice 2013; 41(3): 48 doi: 10.3810/hp.2013.08.1068
39
Philipp Lutz, Marijo Parcina, Isabelle Bekeredjian-Ding, Hans Dieter Nischalke, Jacob Nattermann, Tilman Sauerbruch, Achim Hoerauf, Christian P. Strassburg, Ulrich Spengler, Golo Ahlenstiel. Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and AscitesPLoS ONE 2014; 9(4): e93909 doi: 10.1371/journal.pone.0093909
40
Elliot B. Tapper, Z. Gordon Jiang, Vilas R. Patwardhan. Refining the Ammonia HypothesisMayo Clinic Proceedings 2015; 90(5): 646 doi: 10.1016/j.mayocp.2015.03.003
41
Lewis W. Teperman. Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation OutcomesInternational Journal of Hepatology 2013; 2013: 1 doi: 10.1155/2013/952828
42
Andrea Mancini, Francesca Campagna, Piero Amodio, Kieran M. Tuohy. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathyFood & Function 2018; 9(3): 1373 doi: 10.1039/C7FO01528C
43
Ariadna Ramírez-Polo, Ernesto Márquez-Guillén, Adrián J. González-Aguirre, Iván E. Casanova-Sánchez, Rafael Chávez-Ruiz, Eduardo Carrillo-Maravilla, Eric López-Méndez. Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer deviceAnnals of Hepatology 2014; 13(4): 456 doi: 10.1016/S1665-2681(19)30854-3
44
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal, S K Sarin. A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic EncephalopathyAmerican Journal of Gastroenterology 2013; 108(9): 1458 doi: 10.1038/ajg.2013.219
45
N. Kimer, A. Krag, S. Møller, F. Bendtsen, L. L. Gluud. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathyAlimentary Pharmacology & Therapeutics 2014; 40(2): 123 doi: 10.1111/apt.12803
46
G.-Q. Zhu, K.-Q. Shi, S. Huang, L.-R. Wang, Y.-Q. Lin, G.-Q. Huang, Y.-P. Chen, M. Braddock, M.-H. Zheng. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathyAlimentary Pharmacology & Therapeutics 2015; 41(7): 624 doi: 10.1111/apt.13122
47
Malcolm M. Wells, Thomas D. Schiano. Liver Disorders2017; : 99 doi: 10.1007/978-3-319-30103-7_8
48
Lu Lu, Chao Wu, Bing-jie Lu, Dong Xie, Zheng Wang, Nisma Lena Bahaji Azami, Yong-tong An, Hui-jun Wang, Guan Ye, Ming-yu Sun. BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in ratsJournal of Ethnopharmacology 2020; 249: 112301 doi: 10.1016/j.jep.2019.112301
49
Anna-Lena Laguna de la Vera, Christoph Welsch, Waltraud Pfeilschifter, Jonel Trebicka. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes2021; : 159 doi: 10.1016/B978-0-12-821927-0.00004-8
50
Michael S. Bleszynski, Alexsander K. Bressan, Emilie Joos, S. Morad Hameed, Chad G. Ball. Acute care and emergency general surgery in patients with chronic liver disease: how can we optimize perioperative care? A review of the literatureWorld Journal of Emergency Surgery 2018; 13(1) doi: 10.1186/s13017-018-0194-1